AL Fellows
Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling
Fellows, AL; Quigley, K; Leung, V; Ainscough, AJ; Wilkins, MR; Barnett, H; Miller, D; Mayr, M; Wojciak-Stothard, B
Authors
K Quigley
V Leung
AJ Ainscough
MR Wilkins
H Barnett
D Miller
M Mayr
B Wojciak-Stothard
Abstract
Background and PurposeVasoreactivity of pulmonary arteries regulates blood flow through the lungs. Excessive constriction of these vessels contributes to pulmonary arterial hypertension (PAH), a progressive and incurable condition, resulting in right heart failure. The search for new and improved drug treatments is hampered by laboratory models that do not reproduce the vasoactive behaviour of healthy and diseased human arteries.Experimental ApproachWe have developed an innovative technique for producing miniature, three-dimensional arterial structures that allow proxy evaluation of human pulmonary artery contractility. These "engineered pulmonary artery tissues" or "EPATs" are fabricated by suspending human pulmonary artery vascular smooth muscle cells (VSMCs) in fibrin hydrogels between pairs of silicone posts, located on custom-made racks, in 24-well culture plates.Key ResultsEPATs exhibit rapid, robust and reproducible contraction responses to vasoconstrictors (KCl, ET-1, U46619) as well as relaxation responses to clinically approved PAH vasodilatory drugs that target several signalling pathways, such as bosentan, epoprostenol, selexipag and imatinib. EPATs composed of pulmonary artery VSMCs from PAH patients exhibit enhanced contraction to vasoconstrictors and relaxation in response to vasodilators. We also demonstrate the incorporation of endothelial cells into EPATs for the measurement of endothelium-dependent dilatory responses.Conclusion and ImplicationsWe demonstrate the capacity and suitability of EPATs for studying the contractile behaviour of human arterial cells and preclinical drug testing. This novel biomimetic platform has the potential to dramatically improve our understanding and treatment of cardiovascular disease.
Citation
Fellows, A., Quigley, K., Leung, V., Ainscough, A., Wilkins, M., Barnett, H., Miller, D., Mayr, M., & Wojciak-Stothard, B. (2025). Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling. British Journal of Pharmacology, https://doi.org/10.1111/bph.17462
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 19, 2024 |
Online Publication Date | Feb 20, 2025 |
Publication Date | 2025 |
Deposit Date | Mar 18, 2025 |
Publicly Available Date | Mar 18, 2025 |
Print ISSN | 0007-1188 |
Electronic ISSN | 1476-5381 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1111/bph.17462 |
Keywords | bioengineering; disease modelling; drug testing platform; pulmonary hypertension; vascular pharmacology; SMOOTH-MUSCLE-CELL; HYPERTENSION; RAT; VASOCONSTRICTOR; MECHANISMS; PHENOTYPE; MOUSE; GUIDE |
Files
Engineered Pulmonary Artery Tissues For Measuring Contractility, Drug Testing And Disease Modelling
(5.1 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Version
VoR
Downloadable Citations
About RVC Repository
Administrator e-mail: publicationsrepos@rvc.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search